Additive Manufacturing Today

Upcoming Events

Roboze Argo 500

Roboze announced an initial 3M Euro funding by Equiter SPA, closing Roboze's first round of funding with the largest Italian fund dedicated to research and innovation in Southern Italy and one of the highest funds in Europe. Equiter SPA is an Intesa Sanpaolo Company, CRT and CRC Foundation, selected by EIB (European Investment Bank) for the management of 124 million euros.

"Thanks to our first round of funding we are now positioned to accelerate growth, through the development of new and existing 3D printing technologies and materials, while aggressively pursuing commercial expansion in EMEA and USA." — Alessio Lorusso, CEO & Founder of Roboze.

To date, Roboze has reported 100% year over year growth. Now, the company aims for 500% growth and to reach 80 employees next year. Roboze 3D printers are used in 24 countries worldwide and are supported by strategic territory resellers and partners across the globe.

"The investment of the RIF fund, managed by Equiter, in Roboze comes after careful financial and technical analysis that confirmed the company's potential. It is a market operation, which responds to the intervention logic of private equity, with the objective of accelerating the growth path already started by the Puglia-based company. This investment demonstrates the flexibility and innovation of the financial instruments made available by the European Investment Bank through Miur," commented Enrico Bertoni, general manager of Equiter.

Roboze’s scientific partners and clients include numerous prestigious research centers including: the University of Catania and CNR Catania, the Italian Institute of Technology, the Royal Melbourne Institute of Technology, the Polytechnic University of Turin, the Polytechnic University of Bari and some of the largest opto/electronics research centers and medicine in South Korea.

With the aim of strengthening its positioning in the 3D printing market, this evolution marks increased focus on 3D printing solutions for the manufacturing of functional end-use parts with high-performance polymers and metal replacement even in extreme applications.

The investment will also make it possible to accelerate the development of new technologies and materials for the medical and aeronautical industry, as well as strengthen its presence in the EMEA and USA.

Share This Page

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedIn